Preliminary evidence suggests even that Ruxolitinib as well as the JAK/STAT inhibitor Baricitinib may offer clinical benefit and/or prevent progression to the most severe forms of COVID-19 [33,34,35]. Here, SOAT1 is linked to COVID-19.